Vaccine-associated attenuation of subjective severity among outpatients with influenza
- PMID: 35710506
- PMCID: PMC9638984
- DOI: 10.1016/j.vaccine.2022.06.019
Vaccine-associated attenuation of subjective severity among outpatients with influenza
Abstract
Influenza vaccines can mitigate illness severity, including reduced risk of ICU admission and death, in people with breakthrough infection. Less is known about vaccine attenuation of mild/moderate influenza illness. We compared subjective severity scores in vaccinated and unvaccinated persons with medically attended illness and laboratory-confirmed influenza. Participants were prospectively recruited when presenting for care at five US sites over nine seasons. Participants aged ≥ 16 years completed the EQ-5D-5L visual analog scale (VAS) at enrollment. After controlling for potential confounders in a multivariable model, including age and general health status, VAS scores were significantly higher among 2,830 vaccinated participants compared with 3,459 unvaccinated participants, indicating vaccinated participants felt better at the time of presentation for care. No differences in VAS scores were observed by the type of vaccine received among persons aged ≥ 65 years. Our findings suggest vaccine-associated attenuation of milder influenza illness is possible.
Keywords: Influenza; Vaccines.
Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ‘Dr. Gaglani reports grants from CDC outside the submitted work. Dr. McLean reports grants from Seqirus outside the submitted work. Dr. Nowalk reports grants from Merck & Co outside the submitted work. Dr. Zimmerman reports grants from Sanofi Pasteur outside the submitted work. Dr. L. Jackson reports grants from Novavax outside the submitted work. Dr. Martin reports personal fees from Pfizer outside the submitted work. All other authors have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.’
References
-
- US Centers for Disease Control and Prevention. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths in the United States – 2019–2020 Influenza Season Available from: https://www.cdc.gov/flu/about/burden/2019-2020.html. Accessed November 9.
-
- Putri WCWS, Muscatello DJ, Stockwell MS, Newall AT. Economic burden of seasonal influenza in the United States. Vaccine 2018;36(27):3960–6. - PubMed
-
- Ferdinands JM, Thompson MG, Blanton L, Spencer S, Grant L, Fry AM. Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. Vaccine 2021;39 (28):3678–95. - PubMed
-
- Ye Pan, Du L, Gan Q, Ma W, Wang M, Lu Z, et al. Meta-analysis of whether influenza vaccination attenuates symptom severity in vaccinated influenza patients. Public Health Nurs 2022;39(2):509–16. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1 TR001857/TR/NCATS NIH HHS/United States
- U01 IP000473/IP/NCIRD CDC HHS/United States
- U01 IP000466/IP/NCIRD CDC HHS/United States
- U01 IP001039/IP/NCIRD CDC HHS/United States
- U01 IP000471/IP/NCIRD CDC HHS/United States
- U01 IP000474/IP/NCIRD CDC HHS/United States
- U01 IP000467/IP/NCIRD CDC HHS/United States
- UL1 TR000005/TR/NCATS NIH HHS/United States
- U01IP001039/ACL/ACL HHS/United States
- U01 IP001034/IP/NCIRD CDC HHS/United States
- UL1 RR024153/RR/NCRR NIH HHS/United States
- U01 IP001035/IP/NCIRD CDC HHS/United States
- U01 IP001037/IP/NCIRD CDC HHS/United States
- U01 IP001038/IP/NCIRD CDC HHS/United States
LinkOut - more resources
Full Text Sources
Medical
